HUP0400091A2 - Eljárás antidiabetikus hatású pioglitazon előállítására - Google Patents

Eljárás antidiabetikus hatású pioglitazon előállítására

Info

Publication number
HUP0400091A2
HUP0400091A2 HU0400091A HUP0400091A HUP0400091A2 HU P0400091 A2 HUP0400091 A2 HU P0400091A2 HU 0400091 A HU0400091 A HU 0400091A HU P0400091 A HUP0400091 A HU P0400091A HU P0400091 A2 HUP0400091 A2 HU P0400091A2
Authority
HU
Hungary
Prior art keywords
group
general formula
antidiabetic
hydrogen atom
pioglitazone
Prior art date
Application number
HU0400091A
Other languages
English (en)
Inventor
Ales Halama
Ludmila Hejtmánková
Josef Jirman
Petr Lustig
Jindrich Richter
Lucie Srsnová
Original Assignee
Léciva, a.s.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CZ20011501A external-priority patent/CZ20011501A3/cs
Priority claimed from CZ20011502A external-priority patent/CZ291364B6/cs
Application filed by Léciva, a.s. filed Critical Léciva, a.s.
Publication of HUP0400091A2 publication Critical patent/HUP0400091A2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

A találmány tárgya eljárás az alábbi (I) képletű diabeteszelleneshatóanyag előállítására. Az eljárás értelmében egy alábbi (II)általános képletű, 4-es helyzetben helyettesített fenolt vagyfenolátot - ahol R jelentése aminocsoportot tartalmazó szervesmaradék, amely vagy egy -NHRa általános képletű csoport, ahol Rajelentése hidrogénatom vagy védőcsoport, amelyet a további reagáltatáselőtt eltávolítanak, vagy egy alábbi (i) általános képletű maradék -ahol Rb jelentése karboxilcsoport, amely a szabad sav alakjában vagyészter, vagy egyéb funkcionális származék alakjában van jelen, vagy CNnitrilcsoport, és M jelentése hidrogénatom vagy alkálifématom -, egyalábbi (III) általános képletű piridinbázissal - ahol Z jelentésetávozó csoport, amely halogénatomtól eltérő - kondenzálnak. Ó
HU0400091A 2001-04-26 2002-04-25 Eljárás antidiabetikus hatású pioglitazon előállítására HUP0400091A2 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CZ20011501A CZ20011501A3 (cs) 2001-04-26 2001-04-26 Způsob výroby meziproduktu pro výrobu antidiabetika
CZ20011502A CZ291364B6 (cs) 2001-04-26 2001-04-26 Způsob výroby antidiabetika
PCT/CZ2002/000024 WO2002088120A1 (en) 2001-04-26 2002-04-25 Method for obtaining pioglitazone as an antidiabetic agent

Publications (1)

Publication Number Publication Date
HUP0400091A2 true HUP0400091A2 (hu) 2004-06-28

Family

ID=25746959

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0400091A HUP0400091A2 (hu) 2001-04-26 2002-04-25 Eljárás antidiabetikus hatású pioglitazon előállítására

Country Status (11)

Country Link
US (1) US7009057B2 (hu)
EP (1) EP1387843B1 (hu)
AT (1) ATE355286T1 (hu)
AU (1) AU2002311057A1 (hu)
DE (1) DE60218449D1 (hu)
EE (1) EE200300519A (hu)
HU (1) HUP0400091A2 (hu)
PL (1) PL363738A1 (hu)
RU (1) RU2281285C2 (hu)
SK (1) SK14452003A3 (hu)
WO (1) WO2002088120A1 (hu)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8993773B2 (en) 2002-07-16 2015-03-31 Cadila Healthcare Limited Process to prepare pioglitazone via several novel intermediates
AU2003272072A1 (en) 2002-07-16 2004-02-02 Cadila Healthcare Limited A process to prepare pioglitazone via several intermediates.
WO2004108721A1 (en) * 2003-04-01 2004-12-16 Sun Pharmaceutical Industries Limited Process for the preparation of 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl] methyl]-2,4-thiazolidinedione
ES2219180B1 (es) 2003-05-09 2006-03-01 Medichem, S.A. Compuesto intermedio util para la preparacion de pioglitazona.
US20050059708A1 (en) * 2003-05-13 2005-03-17 Karel Pospisilik Processes for making thiazolidinedione derivatives and compounds thereof
US7230016B2 (en) 2003-05-13 2007-06-12 Synthon Ip Inc. Pioglitazone salts, such as pioglitazone sulfate, and pharmaceutical compositions and processes using the same
US20070078170A1 (en) * 2003-08-28 2007-04-05 Khanduri Chandra H Process for the preparation of pioglitazone
CN1319956C (zh) * 2003-09-12 2007-06-06 深圳市海粤门生物科技开发有限公司 一种噻唑烷二酮的衍生物及其药用制剂的制备方法和应用
WO2005080387A2 (en) 2004-02-20 2005-09-01 Synthon B.V. Processes for making pioglitazone and compounds of the processes
US7402713B2 (en) * 2006-03-07 2008-07-22 E.I. Du Pont De Nemours And Company Processes for conversion of tyrosine to p-hydroxystyrene and p-acetoxystyrene
NZ571871A (en) 2006-03-16 2011-07-29 Metabolic Solutions Dev Co Thiazolidinedione analogues for the treatment of metabolic inflammation mediated disease
EP2001469B1 (en) 2006-03-16 2012-05-23 Metabolic Solutions Development Company LLC Thiazolidinedione analogues
KR100791400B1 (ko) 2006-09-06 2008-01-07 동우신테크 주식회사 티아졸리딘디온 유도체의 제조방법
US8304441B2 (en) 2007-09-14 2012-11-06 Metabolic Solutions Development Company, Llc Thiazolidinedione analogues for the treatment of metabolic diseases
EP2203433B1 (en) 2007-09-14 2012-10-31 Metabolic Solutions Development Company LLC 5-(4-(2-(3-methoxyphenyl)-2-oxoethoxy)benzyl)thiazolidine-2,4-dione for use in treating diabetes
WO2009148195A1 (en) * 2008-06-02 2009-12-10 Daebong Ls, Ltd. 5-(4-hydroxybenzyl)thiazolidine-2,4-dione as intermediate for synthesis of thiazolidinedione based compounds and process for preparing the same
US8912335B2 (en) 2009-12-15 2014-12-16 Metabolic Solutions Development Company, Llc PPAR-sparing thiazolidinedione salts for the treatment of metabolic diseases
CN108003090A (zh) * 2018-01-05 2018-05-08 白银亿尔精细化工有限公司 一种制备4-[2-(5-乙基-2-吡啶基)乙氧基]硝基苯的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57209274A (en) 1981-06-16 1982-12-22 Takeda Chem Ind Ltd Urea derivative, its preparation and its use
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
JPS62205054A (ja) 1986-03-05 1987-09-09 Takeda Chem Ind Ltd 尿素誘導体
US5952509A (en) 1996-06-27 1999-09-14 Takeda Chemical Industries, Ltd. Production of benzaldehyde compounds
JP4316787B2 (ja) * 2000-01-11 2009-08-19 壽製薬株式会社 エーテル又はアミド誘導体、その製法並びにそれを含有する糖尿病治療剤、

Also Published As

Publication number Publication date
SK14452003A3 (sk) 2004-04-06
US20050043360A1 (en) 2005-02-24
RU2003134542A (ru) 2005-06-10
EE200300519A (et) 2004-02-16
AU2002311057A1 (en) 2002-11-11
EP1387843B1 (en) 2007-02-28
WO2002088120A1 (en) 2002-11-07
US7009057B2 (en) 2006-03-07
WO2002088120B1 (en) 2004-02-26
PL363738A1 (en) 2004-11-29
EP1387843A1 (en) 2004-02-11
ATE355286T1 (de) 2006-03-15
RU2281285C2 (ru) 2006-08-10
DE60218449D1 (de) 2007-04-12

Similar Documents

Publication Publication Date Title
HUP0400091A2 (hu) Eljárás antidiabetikus hatású pioglitazon előállítására
ATE348814T1 (de) Verfahren zur herstellung von chinolinderivaten
HUP0402311A2 (hu) Naftiridinszármazékok, eljárás előállításukra, és alkalmazásuk foszfodiészteráz izoenzim 4 (PDE4) gátló hatóanyagként és ezeket tartalmazó gyógyszerkészítmények
BR0311311A (pt) Oximas de arila
RS86804A (en) Quinoline and isoquinoline derivatives method for the production thereof and use therof as anti-inflammatory agents
NO20054201L (no) Fremgangsmate for a framstille N-heteroaryl-N-aminoer ved a reagere en N-aryl-karbaminsyrerester med et halo-heteroaryl og analoge prosesser
HUP0203206A2 (hu) Eljárás 4-trifluormetilszulfinilpirazol-származékok előállítására
BR0215308A (pt) Pirrolopirimidinas
ATE501264T1 (de) Enzymatische verfahren zur herstellung 4- substituierter 3-hydroxybuttersäure-derivate
HUP0401486A2 (hu) Eljárás piridinvegyületek előállítására
HUP0401615A2 (hu) Eljárás L-ribavirin előállítására
BR0213814A (pt) Processos para a fabricação de 3-hidroxi-n, 1,6-trialquil-4-oxo-1, 4-diidro piridino-2-carboxamida
DE60322852D1 (de) Verfahren zur herstellung von eplerenon
DE60213387D1 (de) Zusammensetzungen und verfahren mit platinverbindungen zur nukleinsäuremarkierung
DE69911430D1 (de) Verfahren zur herstellung von 1-(1h)-benzoquinolizin-3-on derivaten
YU45807B (sh) Postopek za pripravo cefodizima
HUP0102124A2 (hu) Eljárás 2-acetiltio-3-fenil-propionsav és sói előállítására
HUP0104067A2 (hu) Új eljárás béta-alanin származék előállítására
ATE419230T1 (de) Verfahren zur herstellung von 2,6-dihalo-para- trifluoromethylanilin
HUP0202865A2 (hu) Eljárás 2-cianopiridin-származékok előállítására
HUP0301306A2 (hu) Gyűrűs ketonok, eljárás azok előállítására és alkalmazásuk aminosavak szintézisében
DE60112241D1 (de) Verfahren und zwischenverbindungen zur herstellung von imidazopyridinen
HUP0401458A2 (hu) Eljárás 4-metilamino-4-fenilpiperidin előállítására
BR0006978A (pt) Processo para preparação de 1,5-diaril-3-pirazóis substituìdos
HUP0400825A2 (hu) Eljárás amorf cilastatin nátrium előállítására

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees